Dokter terbaik untuk pengobatan Sarkoma Ewing di luar negeri — Halaman 2

Dr. Mahmoud M. El Zembely mengepalai departemen onkologi anak di Shefaa Al Orman Cancer Center. Beliau adalah spesialis onkologi anak dan hematologi ganas. Dr. El Zembely menyelesaikan fellowship klinis dalam transplantasi sumsum tulang anak di Seattle Cancer Care Alliance. Beliau menangani berbagai jenis kanker anak, termasuk leukemia, limfoma, dan neuroblastoma.

• Menangani semua jenis leukemia anak, serta limfoma Hodgkin dan non-Hodgkin.
• Menangani tumor padat seperti nefroblastoma, rhabdomyosarcoma, dan kanker anak yang langka.
• Melakukan transplantasi sumsum tulang alogenik dan autologus untuk pasien anak.
• Bekerja di pusat yang terakreditasi ESMO yang menangani 6.000 pasien setiap tahunnya.

Dr. Raanan Berger adalah Direktur Pusat Kanker di Sheba Medical Center. Beliau masuk dalam daftar "Dokter Terbaik" Forbes Israel pada tahun 2025. Dr. Berger berspesialisasi dalam onkologi genitourinari dan melakukan radioterapi pada tumor prostat yang kompleks. Beliau menyelesaikan fellowship pascadoktoral di Dana-Farber/Harvard Cancer Institute.

• Memimpin unit penelitian klinis yang berfokus pada onkologi molekuler.
• Penulis bersama lebih dari 20 makalah yang ditinjau sejawat tentang kanker prostat dan mutasi BRCA.
• Anggota American Society of Clinical Oncology (ASCO).
• Melakukan terapi sistemik dan radioterapi di rumah sakit yang masuk dalam peringkat 10 besar dunia.

Dr. Iris Kventsel adalah hemato-onkolog anak dan spesialis transplantasi sumsum tulang di Sheba Medical Center. Ia menangani sarkoma anak seperti sarkoma Ewing dan osteosarkoma di Rumah Sakit Anak Edmond dan Lily Safra. Dr. Kventsel mengintegrasikan terapi target dengan perawatan seluler untuk kanker anak yang kompleks. Ia bertugas sebagai staf akademik di Fakultas Kedokteran Universitas Tel Aviv.

• Spesialis dalam transplantasi sumsum tulang dan terapi sel CAR-T untuk pasien anak.
• Meneliti predisposisi genetik kanker, termasuk sindrom Li-Fraumeni dan gen kerentanan.
• Menerbitkan karya ilmiah di jurnal utama tentang biologi sel punca dan onkologi bedah (HIPEC).
• Bekerja di Sheba Medical Center, yang termasuk dalam 10 rumah sakit terbaik di dunia.

Dr. Netanel Meushar memimpin departemen kanker tulang di Rambam Medical Center.

• Berspesialisasi dalam pengobatan kanker tulang
• Berpengalaman dalam menangani kasus sarkoma yang kompleks
• Bekerja di pusat medis terkemuka di Israel

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

Prof. Myriam Ben Arush adalah spesialis yang diakui secara internasional dalam Onkologi Anak dan Transplantasi Sumsum Tulang, yang memimpin Divisi Pediatri di Rumah Sakit Anak Ruth Rappaport.

• Penerima Penghargaan Kementerian Kesehatan atas karya luar biasa
• Dianugerahi Chevalier de la Legion d’Honneur di Prancis
• Dinobatkan sebagai salah satu dokter paling peduli di dunia oleh Asosiasi Medis Dunia
• Anggota Children’s Oncology Group di AS dan berbagai organisasi kanker Eropa

Prof. Onder Ofluoglu memiliki pengalaman medis, dengan pelatihan fellowship yang sangat terspesialisasi dalam tumor tulang dan jaringan lunak di University of Pennsylvania dan University of California.

• Berspesialisasi secara eksklusif dalam bedah onkologi ortopedi
• Terlatih dalam bedah Ilizarov di Ilizarov Scientific Center di Rusia
• Penulis atau rekan penulis lebih dari 50 dokumen ilmiah
• Anggota Connective Tissue Oncology Society dan berbagai perkumpulan ortopedi Eropa

Dengan pengalaman lebih dari _doctor_9338_tahun_ di bidang hematologi dan onkologi anak, Prof. Dogru berspesialisasi dalam kanker anak yang kompleks di Rumah Sakit Universitas Biruni.

• Pelatihan onkologi anak khusus di Universitas Istanbul
• Keahlian dalam transplantasi sumsum tulang
• Anggota organisasi Transplantasi Sumsum Tulang Eropa
• Peran sebagai asisten profesor di berbagai universitas bergengsi

Dr. Apak berspesialisasi dalam hematologi dan onkologi anak, dengan keahlian luas dalam transplantasi sumsum tulang dan terapi sel CAR-T di Rumah Sakit Universitas Biruni.

• Lebih dari _doctor_6792_tahun_ memimpin Divisi Hematologi-Onkologi Anak di Universitas Istanbul-Cerrahpaşa
• Menerbitkan 75 makalah internasional tentang perawatan onkologi anak
• Asisten editor untuk jurnal Turkish Pediatrics Archives
• Anggota dewan Masyarakat Pediatri Turki dan Asosiasi Kedokteran Remaja Turki

Ahli bedah ortopedi

Prof. Dr. Suna Emir lulus dari Fakultas Kedokteran Universitas Hacettepe pada tahun 1989. Beliau menyelesaikan residensi pediatri di Universitas Hacettepe dari tahun 1990 hingga 1995. Pada tahun 2001, beliau menyelesaikan subspesialisasi onkologi anak di Institut Onkologi Universitas Hacettepe. Beliau menjadi Profesor Madya pada tahun 2004. Dari tahun 2004 hingga 2009, beliau bekerja di Rumah Sakit Pelatihan dan Penelitian Kesehatan dan Penyakit Anak Ankara Dışkapı dan mendirikan Klinik Onkologi Anak di sana. Pada tahun 2009, beliau menjabat sebagai Wakil Kepala Onkologi Anak. Dari tahun 2009 hingga 2016, beliau adalah petugas pelatihan hematologi-onkologi anak di Rumah Sakit Pelatihan dan Penelitian Kesehatan dan Penyakit Anak, Hematologi-Onkologi Ankara. Sejak 2019, beliau telah menjadi Profesor dan anggota fakultas pendiri di bidang Kesehatan dan Penyakit Anak di Universitas Atilim.

Beliau adalah seorang ahli dalam pediatri umum dan hematologi-onkologi anak. Beliau aktif dalam pelatihan residensi dan subspesialisasi. Minat klinisnya meliputi penyakit masa kanak-kanak dari lahir hingga 18 tahun, limfoma, tumor padat, transplantasi sumsum tulang autologus, anemia, gangguan pendarahan, penyakit darah herediter, hemangioma dan tumor jinak lainnya, serta pembesaran kelenjar getah bening.

Kepala Pusat Onkologi Charité – Dr. Keilholz membawa keahlian tingkat atas untuk kasus kanker yang kompleks.

• Berspesialisasi dalam onkologi dengan fokus pada sarkoma Ewing
• Memimpin salah satu pusat onkologi terkemuka di Berlin

Lebih dari _doctor_3339_tahun_ spesialisasi dalam onkologi anak – Dr. López-Ibor memimpin Unit Hematologi dan Onkologi Anak di HM Montepríncipe.

• Pakar dalam menangani tumor tulang seperti sarkoma Ewing
• Terlatih di University of Maryland, pusat onkologi anak terkemuka di AS
• Mantan kepala onkologi anak di Hospital Universitario Clínica San Rafael
• Memiliki banyak publikasi di jurnal nasional dan internasional

Angelika Eggert adalah Kepala Departemen Onkologi Anak di Charité – salah satu rumah sakit universitas terbesar di Eropa.

• Memimpin departemen utama di rumah sakit terkemuka Eropa
• Fokus secara eksklusif pada pengobatan kanker anak
• Akses ke uji klinis terbaru untuk pasien muda

Dokter Kharya, seorang hematolog-onkolog anak, memiliki spesialisasi dalam transplantasi sumsum tulang untuk kanker anak di Artemis Hospitals.

• Keahlian dalam hematologi dan onkologi anak
• Spesialisasi dalam transplantasi sumsum tulang
• Fokus pada pengobatan kanker anak

Profesor Demirkaya berspesialisasi dalam onkologi anak dengan 27 tahun fokus pada sarkoma Ewing di Rumah Sakit Medicana Bursa.

• Terlatih dalam program residensi onkologi anak di Universitas Bursa Uludag
• Mantan anggota fakultas di Fakultas Kedokteran Universitas Bursa Uludag
• Pernah bekerja di Pusat Hematologi, Onkologi, dan Transplantasi Sumsum Tulang Anak GATA
• Profesor onkologi anak saat ini di Medicana Bursa

Dr. Shruti Kate berspesialisasi dalam sarkoma Ewing dengan keahlian dalam imunoterapi dan terapi metronomik untuk kanker stadium lanjut. Beliau menjalani pelatihan di Tata Memorial Hospital, pusat kanker terkemuka.

• DM dalam Onkologi Medis dari Tata Memorial Hospital
• Anggota ASCO, ESMO, dan perkumpulan onkologi bergengsi lainnya
• Mempresentasikan penelitian tentang kanker paru-paru di WCLC 2018
• Berpengalaman dalam menangani tumor pediatrik dan tumor padat

Dr. Blanca Lopez Ibor memimpin Unit Hematologi & Onkologi Anak di HM Hospitales, dengan pengalaman lebih dari 31 tahun di bidang onkologi anak.

• Berspesialisasi dalam gangguan hematologi dan kanker pada anak-anak dan remaja
• Konsultan WHO dan UNESCO di bidang onkologi anak
• Kepala Fundación Jaime Alonso Abruña, yang membantu anak-anak dengan masalah kesehatan serius
• Anggota International Society of Pediatric Oncology (SIOP)
• Dosen di Universidad Complutense de Madrid dan Universidad CEU San Pablo